Press Release
|
26 March, 2007
飞利浦和Volcano公司在心血管造影方面加强合作。Andover, Mass., and Rancho Cordova, Calif. – Royal Philips Electronics (NYSE: PGH; AEX: PHI) and Volcano Corporation (NASDAQ: VOLC), a developer and manufacturer of intravascular ultrasound (IVUS) systems and imaging catheters, today announced compatibility between the Philips Allura Xper FD systems and the Volcano s5i suite of integrated IVUS systems. This compatibility allows clinicians to quickly and easily connect the Volcano IVUS system with the Allura Xper FD when additional imaging is required to complement cardiovascular X-ray during catheterization (cath) lab procedures. By cutting down the time it takes to set up these key cath lab systems, customers of both companies will optimize workflow and increase productivity. Philips recently completed comprehensive testing to confirm compatibility between its state-of-the-art Allura Xper FD systems and the Volcano s5i suite of integrated IVUS systems and products. The company has acknowledged Volcano as a non-exclusive vendor of choice for new cath lab installations which specify integrated IVUS capabilities, and any Philips customer in a market with Volcano s5i approval can have an integrated IVUS system installed at the time of the new cath lab construction. In addition, this collaboration clears the path for regional co-marketing agreements in important IVUS markets, such as Japan. Bert van Meurs, senior vice president of cardiovascular X-ray for Philips Medical Systems commented, “IVUS is an integral part of daily percutaneous coronary interventions. As the technology and market share leader in the cath lab market in the world, Philips strives to offer the most complete, state-of-the-art integrated cath lab– while retaining optimal work-flows and cath lab efficiency. Volcano’s new s5i IVUS system is uniquely suited to meet those needs, as it integrates into any new cath lab quickly and seamlessly, and provides our customers with integrated IVUS functionality. This collaboration with Volcano should help us meet our customers’ needs and allow Philips to retain its technology and market leadership position.” “In all markets of the world, physicians are increasingly recognizing the clinical value of Volcano’s new intravascular imaging and that it is essential to providing optimal interventional results,” said Scott Huennekens, president and CEO of Volcano Corporation. “Whether it is the use of IVUS to optimize the safe placements of Drug Eluting or Bare Metal Stents or to ensure patients receive a more complete diagnosis of their coronary disease at the time of a diagnostic angiogram, it is more and more clear that a cath lab without integrated IVUS is a cath lab that limits an interventionalist’s capabilities and is not state-of-the-art. From this point forward, any Philips customer desiring integrated IVUS is ensured that their new cath lab is configured for optimal efficiency.” 要了解更多信息，请联络： Ian Race, Public Relations Manager |
|
|